Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Shanghai Fosun Pharmaceutical (Group) Yönetim

Yönetim kriter kontrolleri 3/4

Shanghai Fosun Pharmaceutical (Group)'s CEO'su Deyong Wen, Jan2022 tarihinde atandı, in görev süresi 2.75 yıldır. in toplam yıllık tazminatı CN¥ 10.00M olup, şirket hissesi ve opsiyonları dahil olmak üzere 25.9% maaş ve 74.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.009% ine doğrudan sahiptir ve bu hisseler € 726.32K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2 yıl ve 4.3 yıldır.

Anahtar bilgiler

Deyong Wen

İcra Kurulu Başkanı

CN¥10.0m

Toplam tazminat

CEO maaş yüzdesi	25.9%
CEO görev süresi	2.8yrs
CEO sahipliği	0.004%
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Deyong Wen'un ücretlendirmesi Shanghai Fosun Pharmaceutical (Group)'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥10m	CN¥3m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥8m	CN¥2m	CN¥4b

Tazminat ve Piyasa: Deyong 'nin toplam tazminatı ($USD 1.42M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 3.18M ).

Tazminat ve Kazançlar: Deyong şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.

CEO

Deyong Wen (53 yo)

2.8yrs

Görev süresi

CN¥9,997,000

Tazminat

Mr. Deyong Wen serves as Executive Director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since August 10 2022. He has been a Non-Executive Director at Shanghai Henlius Biotech, Inc. since July 28, 20...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kexin Wang	Executive Co-Chairman	2.8yrs	CN¥15.25m	0.012% € 967.7k
Yifang Wu	Executive Chairman	8.2yrs	CN¥12.14m	0.045% € 3.6m
Deyong Wen	Joint President	2.8yrs	CN¥10.00m	0.0039% € 308.4k
Xiaohui Guan	Executive Vice Chairman	2.8yrs	CN¥9.14m	0.011% € 875.2k
Rongli Feng	Executive President & Chief Human Resources Office	less than a year	Veri yok	0.0043% € 337.6k
Jing Li	Executive President and CEO of Established Medicines Manufacturing & Supply Division	no data	Veri yok	0.0043% € 337.6k
Wang Xingli	Executive President	1.8yrs	Veri yok	Veri yok
Wenjie Zhang	Executive President & Co-CEO of Innovative Drug Division	1.8yrs	Veri yok	Veri yok
Zhanyu Chen	Senior VP & CFO	less than a year	Veri yok	Veri yok
Jia Yan	Director of the Accounting Department	no data	Veri yok	Veri yok
Dongjiu Li	Senior Vice President & Director of Pharmaceutical Commerce Admin Station Committee	3.6yrs	Veri yok	0.0025% € 198.5k
Donghua Wang	Senior VP & Chief Strategic Enabler	4yrs	Veri yok	0.0043% € 337.6k

2.0yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 08HH 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kexin Wang	Executive Co-Chairman	2.8yrs	CN¥15.25m	0.012% € 967.7k
Yifang Wu	Executive Chairman	8.2yrs	CN¥12.14m	0.045% € 3.6m
Deyong Wen	Joint President	2.2yrs	CN¥10.00m	0.0039% € 308.4k
Xiaohui Guan	Executive Vice Chairman	2.8yrs	CN¥9.14m	0.011% € 875.2k
Guliang Tang	Independent Non-Executive Director	5.3yrs	CN¥392.00k	Veri yok
Qiyu Chen	Non-Executive Director	19.4yrs	Veri yok	0.0043% € 339.2k
Xiaoliang Xu	Non-Executive Director	5.3yrs	Veri yok	Veri yok
Tze Shan Yu	Independent Non-Executive Director	3.3yrs	CN¥392.00k	Veri yok
Yuqing Chen	Non-Executive Director	less than a year	Veri yok	0.0058% € 457.8k
Qian Ren	Chairman of Supervisory Committee	6.8yrs	Veri yok	0.00065% € 51.4k
Quandi Wang	Independent Non-Executive Director	3.3yrs	CN¥392.00k	Veri yok
Bing Chen	Chief Supervisor	1.3yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

53.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 08HH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Shanghai Fosun Pharmaceutical (Group) Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Election of Chen Yuqing as Non-Executive Director

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Board and Board Committee Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive and Committee Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 26, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 28, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Appoints Wen Deyong as an Executive Director

Recent updates

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Election of Chen Yuqing as Non-Executive Director

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces in Relation to the Approval for Drug Registration of Licensed Product

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Board and Board Committee Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 23 August 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive and Committee Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 26, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) acquired additional 40% stake in Shanghai Fujian Equity Investment Fund Management Co., Ltd. from Shanghai Fosun Health Industry Holding Company Limited for CNY 22.2 million.

Jiangsu Xingsheng Xinhui Pharmaceutical Co., Ltd. Receives Approval from the National Medical Products Administration of China for the Clinical Trial of XS-03 Tablets

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that it expects to receive CNY 497.7664 million in funding

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces National Medical Products Administration Accepts New Drug Application of Cisplatin Injection

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2023 Results on Aug 29, 2023

Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Approval for Drug Registration of Fosun Kite Biotechnology Co., Ltd

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 28, 2023

BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

Fosun Reportedly Planning Sale of Gland Pharma

China's Fosun Reportedly Said to Mull Sale of India's $3.6 Billion Gland Pharma

Shandong Liancheng Precision Manufacturing Co., Ltd (SZSE:002921) completed the acquisition of 3.9858% stake in Shanghai Shen-li High Tech Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) and Shanghai Fulian Technology Co., Ltd.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2022 Results on Oct 28, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2022 Results on Aug 29, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Appoints Wen Deyong as an Executive Director

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive Appointments

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Recommends Final Dividend for 2021, Dispatch of Cheques for the 2021 Final Dividend Payable on H Shares Is 4 July 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2022 Results on Apr 26, 2022

Insilico Medicine Achieves Its First Major Milestone in Fosun Pharma Collaboration with the Nomination of Preclinical Candidate for QPCTL

Fosun Pharma and Insilico Medicine Announces A Strategic, Ai-Driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets

Tianjin Kingyork Group Co., Ltd. signed the Equity Transfer agreement to acquire an additional 25.0011% stake in Tianjin Pharmaceutical Group Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) for CNY 1.4 billion.

Sisram Medical (Tianjin) Limited completed the acquisition of Shanghai Foshion Medical System Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) and Qianda (Tianjin) International Trading Co., Ltd.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Receives from US FDA Regarding the Clinical Trial of FCN-159 Tablets

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Proposes Final Dividend for 2020

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Update on the License Agreement Entered into by A Subsidiary

BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Management Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2020 Results on Oct 29, 2020

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Elects Zhang Houlin as Non-Executive Director

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Approval for Drug Clinical Trial by A Subsidiary

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) signed an agreement to acquire an additional 10% stake in YaoPharma Co., Ltd. for approximately CNY 740 million.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş